Filing Flows › BioMarin Pharmaceutical (BMRN) › Stock forecast & fair value
BioMarin Pharmaceutical (BMRN) stock forecast and fair value
BioMarin Pharmaceutical (BMRN) trades at $56.03. 27 analysts' median price target is $89.00 (+59%), from $60.00 to $120.00. Across 18 valuation methods the middle fair value is $18.23 (-67%); the DCF says −$4.14.
Fair value by method
| Method | Low | Point | High | vs price |
|---|---|---|---|---|
| Regime-switching Monte Carlo 10th–90th | −$118.57 | $6.78 | $119.58 | -88% |
| DCF — Monte Carlo 10th–90th percentile | −$62.73 | −$4.14 | $41.71 | -107% |
| EV/EBITDA vs peers | −$0.70 | $14.28 | $22.12 | -75% |
| EV/EBITDA vs peers, weighted | $14.39 | $20.61 | $21.77 | -63% |
| EV/EBITDA vs peers, matched | $3.21 | $18.17 | $91.83 | -68% |
| EV/Sales vs peers | $25.32 | $56.71 | $131.59 | +1% |
| EV/Sales vs peers, weighted | $43.32 | $85.80 | $145.22 | +53% |
| EV/Sales vs peers, matched | $21.09 | $37.06 | $67.37 | -34% |
| Residual income | $22.02 | $22.86 | $23.75 | -59% |
| Analysts' price targets | $60.00 | $90.78 | $120.00 | +62% |
BioMarin Pharmaceutical's latest quarter
BioMarin Pharmaceutical, Q3 2026: revenue $1.0B (+32% year over year), operating margin -8.0%, net loss $123M, operating cash flow $188M. The chart follows the revenue to costs, profit and cash.
Questions
What is the price target for BMRN stock?
The median of 27 analysts' 12-month targets is $89.00, +59% from $56.03; the range is $60.00 to $120.00. The average rating is buy.
What is BioMarin Pharmaceutical's fair value?
The fair-value methods on Filing Flows (DCF, Monte Carlo, peer multiples and others) put it between −$4.14 and $90.78, with a middle value of $18.23 against a price of $56.03. Each method's assumptions are on the page.
Does BioMarin Pharmaceutical usually beat earnings estimates?
It beat the consensus EPS estimate in 40% of the quarters on record.
Is BMRN stock a buy?
Filing Flows does not give advice. It shows what analysts expect, what each valuation method implies and the figures behind them, read from SEC filings, so you can judge for yourself.
Updated Nov 8, 2026. Read automatically from SEC filings and public data; errors are possible. Not investment advice.